Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Highlight Therapeutics

Private
#Oncology#Immuno-Oncology#Dermatology#Solid Tumors

Clinical-stage biotechnology company developing RNA-based immune activators that turn cold tumors hot, led by intralesional BO-112 for skin tumors and other solid tumors.

Company Info

Sector:Immuno-Oncology
Headquarters:Paterna (Valencia), Spain
Founded:2010
Website:www.highlighttherapeutics.com/

Clinical Development Pipeline

BO-112

Target: dsRNA / innate immune activation
Resectable basal cell carcinoma (SPOTLIGHT-204)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BO-112 + anti-PD-1

Target: dsRNA / innate immune activation
Cutaneous melanoma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BO-112

Target: dsRNA / innate immune activation
Other advanced solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Zuzana Jirakova Trnkova

Chief Medical Officer

Careers & Job Openings

See all open roles

All departments
Various
Apply Now →